Thermal burn

Preventing Burns In The Workplace - National Safety Month

Retrieved on:

Thursday, June 29, 2023

Buffalo, N.Y., June 29, 2023 Thermal Burns are a common workplace injury that can cause serious harm to employees.

Key Points:

Buffalo, N.Y., June 29, 2023 Thermal Burns are a common workplace injury that can cause serious harm to employees.
Thermal burns are defined as a category of burns caused by:
Preventing thermal burns should be a top priority for employers, as these incidents can lead to serious injury, lost productivity, and decreased morale.
In this blog post, we will explore some effective strategies for preventing thermal burns in the workplace and creating a safe and healthy work environment for all employees.
According to the OSHA article "Preventing Workplace Burns" , under the Occupational Safety and Health Law (OSH), employers have a responsibility to provide a safe workplace.

Prevent Blindness Declares June 28-July 4, 2023, as Third Annual Fireworks Safety Awareness Week, Seeking to Educate the Public on the Dangers of Fireworks

Retrieved on:

Wednesday, June 21, 2023

CHICAGO, June 21, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's oldest nonprofit eye health and safety organization, has declared June 28-July 4, 2023, as the Third Annual Fireworks Safety Awareness Week. According to the Consumer Product Safety Commission (CPSC), fireworks devices were involved in an estimated 8,500 injuries treated in U.S. hospital emergency departments around the 4th of July holiday in 2021. And, there were 9 non-occupational, fireworks-related deaths during that time period.

Key Points:

CHICAGO, June 21, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's oldest nonprofit eye health and safety organization, has declared June 28-July 4, 2023, as the Third Annual Fireworks Safety Awareness Week.
Prevent Blindness also offers fun and creative ideas for fireworks alternatives for safe celebrations .
"Have a safe Independence Day this year by leaving the fireworks to licensed professionals," said Jeff Todd, president and CEO of Prevent Blindness.
"And remember to be vigilant about your surroundings, as bystanders can also be injured by errant fireworks and shrapnel."

Ninja Foodi Pressure Cooker Lawsuit Filed in Texas

Retrieved on:

Tuesday, February 21, 2023

SharkNinja, Explosion, Lawyer, Multimedia, Safety, Burn, Complaint, Thermal burn, PLLC, Pressure, Insurance

Johnson//Becker filed this complaint alleging that SharkNinja, the manufacturer of the Ninja Foodi pressure cooker , misrepresented the safety of its pressure cookers.

Key Points:

Johnson//Becker filed this complaint alleging that SharkNinja, the manufacturer of the Ninja Foodi pressure cooker , misrepresented the safety of its pressure cookers.
The Complaint alleges that Ms. Morrison's pressure cooker exploded while under pressure.
Questions About a Ninja Foodi Pressure Cooker Lawsuit?
We are actively filing new Ninja Food pressure cooker lawsuits across the country, and you may be entitled to financial compensation.

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

Retrieved on:

Thursday, December 29, 2022

Clinical trial, Standard of care, TBSA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SOC, Trial of the century, Patient, Sports medicine, Massachusetts General Hospital, Eschar, Bromelain (pharmacology), FDA, Body surface area, Thermal burn, Incidence, Pharmaceutical industry, Vericel, MD

CAMBRIDGE, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.

Key Points:

“There is a considerable unmet need for non-surgical eschar removal for patients with severe thermal burns, and the FDA’s approval of NexoBrid marks an important advancement in the treatment paradigm for these patients,” said Nick Colangelo, President and CEO of Vericel.
A key safety endpoint, non-inferiority in time to >95% wound closure compared with patients treated with SOC, was also achieved.
A first application of NexoBrid may be applied to an area of up to 15% body surface area.
A second application of NexoBrid may be applied 24 hours later, with a total treated area for both applications of up to 20% TBSA.

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

Retrieved on:

Thursday, November 10, 2022

GLOBE, Financial Services Forum, Knee, Debridement, Sports medicine, Investor relations, CG, Webcast, NASDAQ, Digital health, CFO, Company, Conference, Chondrocyte, Patient, CEO, Thermal burn, Pharmaceutical industry, Diagnosis

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Key Points:

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.
Nick Colangelo, President and CEO will present at the CG MedTech, Diagnostics, and Digital Health & Service Forum at 10:00 a.m.
ET at the Stephens Annual Investment Conference.
Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .

Vericel Reports Third Quarter 2022 Financial Results

Retrieved on:

Wednesday, November 9, 2022

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2022.

Key Points:

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2022.
Total net revenue for the quarter ended September 30, 2022 increased 12% to $38.6 million, compared to $34.5 million in the third quarter of 2021.
Gross profit for the quarter ended September 30, 2022 was $25.2 million, or 65% of net revenue, compared to $22.1 million, or 64% of net revenue, for the third quarter of 2021.
Total operating expenses for the quarter ended September 30, 2022 were $32.0 million, compared to $27.1 million for the same period in 2021.

Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022

Retrieved on:

Wednesday, October 26, 2022

Knee, NASDAQ, Debridement, Software, Vericel, Webcast, Patient, Sports medicine, GLOBE, Telephone, Thermal burn, Chondrocyte, Investor relations, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022.

Key Points:

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022.
Vericels management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations .
Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

Retrieved on:

Thursday, September 22, 2022

Debridement, Knee, Sports medicine, Patient, Investor relations, Chondrocyte, NASDAQ, Conference, GLOBE, Thermal burn, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference.

Key Points:

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets.
NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation.

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

Retrieved on:

Tuesday, September 6, 2022

Thermal burn, CEO, Knee, NASDAQ, Morgan, Morgan Stanley, Sports medicine, Investor relations, Chondrocyte, CFO, GLOBE, Conference, Company, Patient, Debridement, Pharmaceutical industry

Nick Colangelo, President and CEO, and Joe Mara, CFO will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 8:00 a.m.

Key Points:

Nick Colangelo, President and CEO, and Joe Mara, CFO will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 8:00 a.m.
On Wednesday, September 14, 2022, Mr. Mara will engage in a fireside chat at 9:00 a.m.
ET at the H.C. Wainwright 24th Annual Global Investment Conference.
Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .

Vericel Reports Second Quarter 2022 Financial Results

Retrieved on:

Wednesday, August 3, 2022

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2022.

Key Points:

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2022.
Total net revenue for the quarter ended June 30, 2022 was $37.0 million, compared to $39.5 million in the second quarter of 2021.
Gross profit for the quarter ended June 30, 2022 was $22.9 million, or 62% of net revenue, compared to $26.9 million, or 68% of net revenue, for the second quarter of 2021.
Non-GAAP adjusted EBITDA for the quarter ended June 30, 2022 was $2.8 million, or 7% of net revenue, compared to $7.8 million, or 20% of net revenue, for the second quarter of 2021.